CompletedNCT03197168
Official study titleImplementing a Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among Mental Health Outpatients in Chile: a Pilot Randomized Controlled Trial
This study has finished and is no longer accepting participants.
In SantiagoSchizophrenia, BipolarityBehavioural studyAges 18–45
- Countries
- Chile
- Sponsor
- University of Chile
CompletedNCT00595504
Official study titlePhase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In BostonSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Massachusetts General Hospital (Hospital / academic medical center)
CompletedNCT00645944
What is this study about?Researchers compared Eszopiclone and placebo to find out how the approaches affected sleep difficulties in people with schizophrenia.
This study has finished and is no longer accepting participants.
In New HavenSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT02074319
Official study titleA Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia
This study has finished and is no longer accepting participants.
In KarachiSchizophreniaMedication studyAges 18–35
- Countries
- Pakistan
- Sponsor
- Pakistan Institute of Living and Learning
CompletedNCT02869334
Official study titleRemediation of Auditory Recognition in Schizophrenia With Transcranial Direct Current Stimulation (tDCS)
This study has finished and is no longer accepting participants.
In New YorkSchizophreniaDevice studyAges 18–55
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
CompletedNCT00995553
What is this study about?Researchers compared training for memory, attention and thinking skills and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
This study has finished and is no longer accepting participants.
In MinneapolisSchizophreniaBehavioural studyAges 18–60
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
CompletedNCT00313391
Official study titleThe Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients
This study has finished and is no longer accepting participants.
In AtlantaSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Emory University
CompletedNCT01880255
Official study titleRepetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Working Memory Deficits in Schizophrenia and Effects on Brain Structure
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaDevice studyAges 18–59
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT00480571
What is this study about?Researchers compared BL-1020 and BL 1020 High Dose, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Tel HaShomerSchizophreniaMedication studyAges 18–65
- Countries
- Israel, Romania
- Sponsor
- BioLineRx, Ltd.
WithdrawnNCT00702793
Official study titleSafety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial
This study was withdrawn before enrollment.
Location not clearly listedSchizophreniaMedication studyAges 19–65
- Countries
- Sponsor
- University of British Columbia
CompletedNCT01556763
Official study titleA Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics
This study has finished and is no longer accepting participants.
In WichitaSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- FORUM Pharmaceuticals Inc
CompletedNCT01578486
Official study titleSalsalate as an Adjunctive Treatment for Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In WorcesterSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- University of Massachusetts, Worcester